OncoResponse raises $40M Series B to advance five antibody-based cancer immunotherapies into preclinical and clinical trials
OncoResponse raised $40 million in a Series B to push five antibody-based cancer immunotherapy candidates into preclinical and clinical studies, bringing total funding to nearly $70 million since its 2015 launch. The company mines antibodies from cancer patients who had exceptional responses to immunotherapy to develop treatments that modulate tumor‑microenvironment immunosuppression.